SEC Form 4 · accession 0001140361-16-056412
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew H Galligan
Officer — Chief Financial Officer
Period of report
Dec 29, 2015
Accepted (ET)
Mar 3, 2016 · 6:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 29, 2015 | M | 4,500 | $1.44 | A | 4,500 | D | |
| Common Stock | Mar 1, 2016 | M | 10,000 | $1.44 | A | 14,500 | D | |
| Common StockF2 | Mar 1, 2016 | S | 300 | $52.2965 | D | 14,200 | D | |
| Common StockF3 | Mar 1, 2016 | S | 1,202 | $53.8978 | D | 12,998 | D | |
| Common StockF4 | Mar 1, 2016 | S | 1,384 | $54.8109 | D | 11,614 | D | |
| Common StockF5 | Mar 1, 2016 | S | 3,100 | $56.0654 | D | 8,514 | D | |
| Common StockF6 | Mar 1, 2016 | S | 3,314 | $56.7359 | D | 5,200 | D | |
| Common StockF7 | Mar 1, 2016 | S | 600 | $57.6792 | D | 4,600 | D | |
| Common StockF8 | Mar 1, 2016 | S | 100 | $59.06 | D | 4,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9 | $1.44 | Dec 29, 2015 | M | 4,500 | D | — | May 17, 2020 | Common Stock | 4,500 | 72,904 | D |
| Stock Option (Right to Buy)F9 | $1.44 | Mar 1, 2016 | M | 10,000 | D | — | May 17, 2020 | Common Stock | 10,000 | 62,904 | D |
Explanation of responses
- F1The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.61, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $53.21 to $54.1980, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $54.32 to $55.3103, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $55.42 to $56.3882, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $56.42 to $57.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $57.45 to $57.85, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $58.85 to $59.35, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9100% of the shares subject to the option are fully vested and exercisable.